Pub Date : 2024-09-01DOI: 10.1097/MJT.0000000000001733
Courtney Mackzum, Ronda Ambroziak, Chanda Mullen, Jenna Garlock
{"title":"Evaluating Safety of Morphine Sulfate Use in Noncritically Ill Patients With Acute Kidney Injury in the Hospital Setting.","authors":"Courtney Mackzum, Ronda Ambroziak, Chanda Mullen, Jenna Garlock","doi":"10.1097/MJT.0000000000001733","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001733","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"31 5","pages":"e580-e584"},"PeriodicalIF":2.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-30DOI: 10.1097/MJT.0000000000001766
Fouad Jaber, Mohammed Ayyad, Saqr Alsakarneh, Tala Alsharaeh, Ahmed-Jordan Salahat, Mohammad Jaber, Manesh Kumar Gangwani, Yazan Abboud, Islam Mohamed, Hassam Ali, Yassine Kilani, Francis A Farraye, Jana G Hashash
Background: Targeting interleukin-23 (IL-23) represents a significant therapeutic avenue for treating ulcerative colitis (UC).
Study question: What are the effectiveness and safety of selective inhibitors targeting IL-23p19 and IL-12/23p40 in individuals with moderate-to-severe UC?
Data sources: MEDLINE, Embase, Scopus, and Cochrane databases.
Study design: A systematic search of MEDLINE, Embase, Scopus, and Cochrane databases till January 15, 2024, to identify randomized controlled trials comparing IL-23p19 and IL-12/23p40 inhibitors against placebo or active comparators in UC patients. The primary outcome was clinical remission, with secondary outcomes including clinical response, endoscopic remission, and safety profiles during induction and maintenance phases. Using a fixed-effect model, we pooled dichotomous data with risk ratio (RR) and 95% confidence interval (CI) for analysis.
Results: In 5 trials involving 1120 patients with moderate to severe UC, targeting IL-23 showed significant superiority in inducing clinical remission [RR: 2.08, 95% CI, (1.66-2.61)], endoscopic remission [RR: 1.73, 95% CI, (1.39-2.16)], and histologic remission [RR: 1.88, 95% CI, (1.34-2.64)]. Additionally, individuals treated with IL-12/23p40 or IL-23p19 antagonists maintained clinical remission [RR: 1.85, 95% CI, (1.53-2.23)], endoscopic remission [RR: 2.03, 95% CI, (1.60-2.57)], and histologic remission [RR: 1.66, 95% CI, (1.11-2.48)]. Targeting IL-23 was linked with a reduced risk of any adverse events (AE) during both induction [RR: 0.94, 95% CI, (0.86-1.02)] and maintenance phases [RR: 0.93, 95% CI, (0.86-0.99)], any serious AE during the induction phase [RR: 0.53, 95% CI, (0.36-0.78)], and withdrawal due to AEs compared to patients receiving placebo during induction [RR: 0.24, 95% CI (0.14, 0.43)].
Conclusion: Targeting IL-23 demonstrates efficacy and safety for inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC patients.
{"title":"Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review Ad Meta-Analysis of Randomized Controlled Trials.","authors":"Fouad Jaber, Mohammed Ayyad, Saqr Alsakarneh, Tala Alsharaeh, Ahmed-Jordan Salahat, Mohammad Jaber, Manesh Kumar Gangwani, Yazan Abboud, Islam Mohamed, Hassam Ali, Yassine Kilani, Francis A Farraye, Jana G Hashash","doi":"10.1097/MJT.0000000000001766","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001766","url":null,"abstract":"<p><strong>Background: </strong>Targeting interleukin-23 (IL-23) represents a significant therapeutic avenue for treating ulcerative colitis (UC).</p><p><strong>Study question: </strong>What are the effectiveness and safety of selective inhibitors targeting IL-23p19 and IL-12/23p40 in individuals with moderate-to-severe UC?</p><p><strong>Data sources: </strong>MEDLINE, Embase, Scopus, and Cochrane databases.</p><p><strong>Study design: </strong>A systematic search of MEDLINE, Embase, Scopus, and Cochrane databases till January 15, 2024, to identify randomized controlled trials comparing IL-23p19 and IL-12/23p40 inhibitors against placebo or active comparators in UC patients. The primary outcome was clinical remission, with secondary outcomes including clinical response, endoscopic remission, and safety profiles during induction and maintenance phases. Using a fixed-effect model, we pooled dichotomous data with risk ratio (RR) and 95% confidence interval (CI) for analysis.</p><p><strong>Results: </strong>In 5 trials involving 1120 patients with moderate to severe UC, targeting IL-23 showed significant superiority in inducing clinical remission [RR: 2.08, 95% CI, (1.66-2.61)], endoscopic remission [RR: 1.73, 95% CI, (1.39-2.16)], and histologic remission [RR: 1.88, 95% CI, (1.34-2.64)]. Additionally, individuals treated with IL-12/23p40 or IL-23p19 antagonists maintained clinical remission [RR: 1.85, 95% CI, (1.53-2.23)], endoscopic remission [RR: 2.03, 95% CI, (1.60-2.57)], and histologic remission [RR: 1.66, 95% CI, (1.11-2.48)]. Targeting IL-23 was linked with a reduced risk of any adverse events (AE) during both induction [RR: 0.94, 95% CI, (0.86-1.02)] and maintenance phases [RR: 0.93, 95% CI, (0.86-0.99)], any serious AE during the induction phase [RR: 0.53, 95% CI, (0.36-0.78)], and withdrawal due to AEs compared to patients receiving placebo during induction [RR: 0.24, 95% CI (0.14, 0.43)].</p><p><strong>Conclusion: </strong>Targeting IL-23 demonstrates efficacy and safety for inducing and maintaining clinical and endoscopic remission in moderate-to-severe UC patients.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28DOI: 10.1097/MJT.0000000000001821
Richard Isralowitz, Patricia A Findley, Alexander Reznik
{"title":"Attitudes and Knowledge of Medical Students in South of Israel Toward Medical Cannabis.","authors":"Richard Isralowitz, Patricia A Findley, Alexander Reznik","doi":"10.1097/MJT.0000000000001821","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001821","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-27DOI: 10.1097/MJT.0000000000001799
Mohammad Tanashat, Osama Bisht, Mohamed Abuelazm, Obieda Altobaishat, Ubaid Khan, Mohamed Abouzid
{"title":"Transthyretin Stabilizers Treatment in Patients With Transthyretin-Mediated Cardiac Amyloidosis: A Systematic Review and Meta-Analysis.","authors":"Mohammad Tanashat, Osama Bisht, Mohamed Abuelazm, Obieda Altobaishat, Ubaid Khan, Mohamed Abouzid","doi":"10.1097/MJT.0000000000001799","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001799","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-27DOI: 10.1097/MJT.0000000000001802
Sai Spoorthy Penumarthi, Bhavani Lalkota, Shivani Jangili, Shruthi Salla, Santhosh Reddy Satti, Shantan Venishetty, Manasa Alla, Sowmya Iyengar, Mithun Sharma, P N Rao, D Nageshwar Reddy, Anand V Kulkarni
{"title":"Short-Term Primary Rifaximin Prophylaxis Has No Beneficial Role in Patients With Cirrhosis.","authors":"Sai Spoorthy Penumarthi, Bhavani Lalkota, Shivani Jangili, Shruthi Salla, Santhosh Reddy Satti, Shantan Venishetty, Manasa Alla, Sowmya Iyengar, Mithun Sharma, P N Rao, D Nageshwar Reddy, Anand V Kulkarni","doi":"10.1097/MJT.0000000000001802","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001802","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-22DOI: 10.1097/MJT.0000000000001801
Li Li, Yong-Ping Chen, Ya He, Min Wang, Sheng-Li Chen, Li-Na Zhang
{"title":"Impact of L-PGDS Suppression on Cerebral Ischemia/Reperfusion Injury Through the PPARγ/AMPK/mTOR Pathway: Clinical Implications for Therapeutic Intervention.","authors":"Li Li, Yong-Ping Chen, Ya He, Min Wang, Sheng-Li Chen, Li-Na Zhang","doi":"10.1097/MJT.0000000000001801","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001801","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142035025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-21DOI: 10.1097/MJT.0000000000001786
Audra Boscoe, Rebecca McCracken, Punit Marathe, Kareem Osman
{"title":"Response to Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.","authors":"Audra Boscoe, Rebecca McCracken, Punit Marathe, Kareem Osman","doi":"10.1097/MJT.0000000000001786","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001786","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-21DOI: 10.1097/MJT.0000000000001818
Yujie Liang, Wenxing Xu, Weijie He
{"title":"Comparing Intravenous Dexmedetomidine With Midazolam in Patients Undergoing Bronchoscopy: A Meta-analysis of Randomized Controlled Trials.","authors":"Yujie Liang, Wenxing Xu, Weijie He","doi":"10.1097/MJT.0000000000001818","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001818","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号